Diabetic Eye Articles & Analysis: Older
11 news found
Diabetic eye diseases are treatable, and blindness can be prevented for most patients with early detection and treatment. However, in some areas as low as 15% of people with diabetes get the recommended annual diabetic eye exam to test for DR and DME. “Using innovative technology like IDx-DR gives us the ...
Additionally, diabetic retinopathy, the most feared complication of diabetes and the primary overall cause of blindness from any disease, has a prevalence from 19.7 percent to 44.7 percent in Saudi Arabia. ...
Additionally, a symposium titled, “Cellular senescence and immune response in ocular health and disease,” featured leading researchers in the field who discussed the role of cellular senescence and aging in various eye diseases, as well as promising therapeutic approaches to target this pathway. ...
“The Phase 2 study enables us to further explore whether UBX1325 may provide improved treatment options for patients with wAMD in parallel with our ongoing Phase 2 study, BEHOLD, in diabetic macular edema. We continue to advance our ophthalmology programs, with a sharpened focus into the next stage of development and remain on track to announce data from both studies over ...
(“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, has completed enrollment for the BEHOLD study, its Phase 2 clinical trial of UBX1325 in patients with diabetic macular edema (DME). “Patients with advanced retinovascular diseases, including DME, shoulder a significant burden with current ...
Digital Diagnostics created IDx-DR, the autonomous AI diagnostic system for the detection of diabetic retinopathy (including diabetic macular edema) at the point-of-care. Only 15% of people with diabetes receive the recommended annual diabetic eye exam.[1],[2] Access to effective diagnostic services is an ...
24-week UBX1325 Phase 1 data presented at Angiogenesis, Exudation, and Degeneration 2022 Conference Patients with diabetic macular edema (DME) and wet age-related macular degeneration (wAMD) showed improvement in visual acuity through 24 weeks following single dose of UBX1325 Phase 2 clinical studies of UBX1325 currently enrolling patients with DME and wAMD UNITY ...
CMS’ CY 2022 Medicare Physician Fee Schedule (MPFS) and CY 2022 Outpatient Prospective Payment System (OPPS) final regulations, published today, will help to create equitable access to the diabetic eye exam across the country. Specifically, today’s rules mark the first national payment for the IDx-DR service in the physician office setting (CPT code ...
“There are over 8 million people with diabetes in Bangladesh, many of whom don’t have access to the care they need, such as routine diabetic eye exams,” said Michael Abramoff, MD, PhD, Founder and Executive Chairman of Digital Diagnostics. ...
Optos, a Fife based company and a world-leader in the design and manufacturing of advanced retinal imaging technology, has been awarded NHS funding to accelerate the implementation and validation of Artificial Intelligence (AI) to support the early detection of Diabetes related eye-disease into NHS Diabetic Eye Screening ...
(“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that clinical data results from the Phase 1 study of its lead senolytic candidate, UBX1325, in patients with diabetic macular edema and wet age-related macular degeneration will be presented at the Association for Research in Vision and ...